Vanguard Group Inc Galectin Therapeutics Inc Transaction History

Vanguard Group Inc

$5.97 Trillion
Q2 2025

A detailed history of Vanguard Group Inc transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Vanguard Group Inc holds 2,184,548 shares of GALT stock, worth $9.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,184,548

Previous 2,192,502 0.36%

Holding current value

$9.28 Million

Previous $2.67 Million 72.36%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 11, 2025	SELL	$1.25 - $3.29 $9,942 - $26,168	-7,954 Reduced 0.36%	2,184,548 $4.61 Million
Q1 2025 May 09, 2025	BUY	$1.1 - $1.76 $60,388 - $96,622	54,899 Added 2.57%	2,192,502 $2.67 Million
Q4 2024 Feb 11, 2025	BUY	$0.87 - $3.0 $2,956 - $10,194	3,398 Added 0.16%	2,137,603 $2.54 Million
Q3 2024 Nov 13, 2024	BUY	$2.04 - $2.86 $36,991 - $51,860	18,133 Added 0.86%	2,134,205 $5.87 Million
Q2 2024 Aug 13, 2024	BUY	$2.13 - $4.2 $290,065 - $571,960	136,181 Added 6.88%	2,116,072 $4.78 Million
Q1 2024 May 10, 2024	BUY	$1.6 - $2.44 $60,859 - $92,810	38,037 Added 1.96%	1,979,891 $4.73 Million
Q4 2022 Feb 10, 2023	BUY	$1.03 - $1.66 $1,078 - $1,738	1,047 Added 0.05%	1,941,854 $2.19 Million
Q1 2022 May 13, 2022	SELL	$1.61 - $2.31 $15,908 - $22,825	-9,881 Reduced 0.51%	1,940,807 $3.13 Million
Q4 2021 Feb 14, 2022	SELL	$2.07 - $3.8 $5,653 - $10,377	-2,731 Reduced 0.14%	1,950,688 $4.04 Million
Q2 2021 Aug 13, 2021	BUY	$2.07 - $5.1 $4.04 Million - $9.96 Million	1,953,419 New	1,953,419 $6.25 Million

Others Institutions Holding GALT

# of Institutions

Shares Held

11.2M

Call Options Held

134K

Put Options Held

353K

View Full List

About GALECTIN THERAPEUTICS INC

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $253M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

More about GALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Galectin Therapeutics Inc Transaction History